McKesson (MCK) Q2 2025 Earnings
McKesson reported Q2 2025 revenue of $97.8B (+23.4% YoY), beat analyst consensus of $96.2B by $1.6B. Diluted EPS came in at $8.26 (+4.8% YoY), beat the $8.14 consensus by $0.12. McKesson reports across 4 business segments, led by U.S. Pharmaceutical, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).
Financial Snapshot
Trailing eight quarters through Q2 2025
Q2 2025 Earnings FAQ
Common questions about McKesson's Q2 2025 earnings report.
McKesson (MCK) reported Q2 2025 earnings on August 6, 2025 after market close.
McKesson reported revenue of $97.8B and diluted EPS of $8.26 for Q2 2025.
Revenue beat the consensus estimate of $96.2B by $1.6B. EPS beat the consensus estimate of $8.14 by $0.12.
Compared to the same quarter a year prior, revenue grew 23.4% from $79.3B a year earlier and diluted EPS grew 4.8% from $7.88.
You can read the 10-Q periodic report (0000927653-25-000107) directly on SEC EDGAR. The filing index links above go to sec.gov.